
-
Athira Pharma NasdaqCM:ATHA Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Location: 18706 North Creek Parkway, Bothell, WA, 98011, United States | Website: https://www.athira.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-40.13M
Cash
51.28M
Avg Qtr Burn
-24.29M
Short % of Float
3.40%
Insider Ownership
8.27%
Institutional Own.
47.17%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Fosgonimeton (ATH-1017) Details Parkinson's disease, Dementia | Phase 2 Update | |
ATH-1105 Details Amyotrophic lateral sclerosis | Phase 1 Data readout | |
Fosgonimeton (ATH-1017) Details Alzheimer's disease | Failed Discontinued |